AnalystBro Research

Research

Company valuation reports, peer comparisons, results notes, industry reports and macro views, built from company filings and official data and independently reviewed before publishing. Company reports show their full model as view-only sheets. Facts and estimates, not investment advice.

2 articles.

Company · DSE:IBNSINA · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026

IBN SINA Pharmaceutical: 9M FY2026 sales up 18% as the Mawna plant lifts capital work-in-progress to BDT 4.1bn, funded mostly with debt

Sales rose every year for ten years, at 4.5-24.6% a year, with steady 40-42% gross margins; selling and distribution takes 30% of revenue, so ROE fell from 24-25% to 17% in FY2025. The FY2026 cash dividend is 77%, the highest yet.

Company · DSE:ACMELAB · Pharmaceuticals · Initiation · 29 Oct 2026

ACME's debt took 48% of FY2025 operating profit, limiting fair value to BDT 65–137 (base 105)

Fair value BDT 65–137 (base 105) vs price 77.9; domestic sales grow ~11% and own API helps margins; a weaker taka on imported APIs and interest on BDT 23bn of debt are the risks.

Fair value ৳65–137 · price ৳77.90 (2026-10-29)